Araştırma Makalesi

Distribution of hepatitis C virus genotypes in Ordu province

Cilt: 16 Sayı: 1 25 Mart 2025
PDF İndir
EN TR

Distribution of hepatitis C virus genotypes in Ordu province

Öz

Aim: Hepatitis C virus (HCV) infection is a major health problem worldwide and leads to chronic liver disease, cirrhosis, and hepatocellular carcinoma. Genotype 1, the most common genotype worldwide, usually requires longer and more complex treatment regimens compared to other genotypes. HCV infection is closely associated with changes in liver enzyme levels, especially alanine aminotransferase (ALT). This study aims to determine the distribution of HCV genotypes in chronic HCV patients and to investigate the relationship between HCV genotype and serum ALT levels. Material and Methods: In this retrospective study, the outcomes of patients diagnosed with chronic liver disease due to HCV at Ordu University Medical Faculty, Education and Research Hospital between May 2021 and October 2023 were analyzed. HCV genotyping was performed using the Bosphore HCV Genotyping Kit v5 (Anatolia Geneworks, Türkiye) according to the manufacturer's instructions. Serum ALT levels were measured using the electrochemiluminescence immunoassay method (Cobas e 601, Roche, Germany). Results: A total of 219 HCV-RNA positive patients were included in the study. Of all patients, 125 (57.1%) were female and 94 (42.9%) were male. When genotype distribution was examined, it was seen that 200 patients (91.3%) had genotype 1b, 9 patients (4.1%) had genotype 1a, 7 patients (3.2%) had genotype 3, 2 patients (0.9%) had genotype 1, and 1 patient (0.5%) had genotype 4. A total of 9 patients had serum ALT levels above 40 IU/L. Conclusion: Genotype 1b remains the most frequently detected genotype among our patients, while the prevalence of Genotype 3 has changed over the years. No significant differences were found in serum ALT levels, mean age, and gender distribution between patients infected with Genotype 1 and other genotypes.

Anahtar Kelimeler

Destekleyen Kurum

Yazarlar bu çalışmanın hiçbir mali destek almadığını beyan etmişlerdir.

Etik Beyan

Bu çalışma Ordu Üniversitesi Araştırma Enstitüsü Klinik Araştırmalar Etik Kurulu tarafından onaylanmıştır (270/10.11.2023).

Teşekkür

Yok

Kaynakça

  1. Roger S, Ducancelle A, Le Guillou-Guillemette H, Gaudy C, Lunel F. HCV virology and diagnosis. Clin Res Hepatol Gastroenterol. 2021;45(3):101626.
  2. Ferri S, Muratori L, Lenzi M, Granito A, Bianchi FB, Vergani D. HCV and autoimmunity. Curr Pharm Des. 2008;14(17):1678-85.
  3. Nahon P, Cobat A. Human genetics of HCV infection phenotypes in the era of direct-acting antivirals. Hum Genet. Haziran 2020;139(6-7):855-63.
  4. Nutini MFR, Hunter J, Giron L, Pires AFNPC, Kohiyama IM, Camargo M, et al. HCV genotype profile in Brazil of mono-infected and HIV co-infected individuals: A survey representative of an entire country. PLoS One. 2020;15(1):e0227082.
  5. Hajarizadeh B, Lamoury FM, Feld JJ, Amin J, Keoshkerian E, et al. Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection. Virol J. Aralık 2016;13(1):32.
  6. Sakagishi Y. Alanine aminotransferase (ALT). Nihon Rinsho Jpn J Clin Med. 1995;53(5):1146-50.
  7. Kanda T, Matsumoto N, Ishii T, Arima S, Shibuya S, Honda M, et al. Chronic hepatitis C: Acute exacerbation and alanine aminotransferase flare. Viruses. 2023;15(1):183.
  8. Baharlou R, Romani B, Kiani SJ, Sadeghi K, Shadmand E, Fazel H, et al. Genotype-related variations in proinflammatory and regulatory cytokine levels in treated and treatment-naive HCV-infected patients. Med Microbiol Immunol (Berl). 2018;207(1):65-74.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Klinik Mikrobiyoloji

Bölüm

Araştırma Makalesi

Yayımlanma Tarihi

25 Mart 2025

Gönderilme Tarihi

23 Eylül 2024

Kabul Tarihi

23 Ocak 2025

Yayımlandığı Sayı

Yıl 2025 Cilt: 16 Sayı: 1

Kaynak Göster

APA
Kalaycı, H. Ö., Çalgın, M. K., Erdal, H., & Gürpınar, A. B. (2025). Distribution of hepatitis C virus genotypes in Ordu province. Turkish Journal of Clinics and Laboratory, 16(1), 1-6. https://doi.org/10.18663/tjcl.1554814
AMA
1.Kalaycı HÖ, Çalgın MK, Erdal H, Gürpınar AB. Distribution of hepatitis C virus genotypes in Ordu province. TJCL. 2025;16(1):1-6. doi:10.18663/tjcl.1554814
Chicago
Kalaycı, Hacer Özlem, Mustafa Kerem Çalgın, Hüseyin Erdal, ve Ahmet Burak Gürpınar. 2025. “Distribution of hepatitis C virus genotypes in Ordu province”. Turkish Journal of Clinics and Laboratory 16 (1): 1-6. https://doi.org/10.18663/tjcl.1554814.
EndNote
Kalaycı HÖ, Çalgın MK, Erdal H, Gürpınar AB (01 Mart 2025) Distribution of hepatitis C virus genotypes in Ordu province. Turkish Journal of Clinics and Laboratory 16 1 1–6.
IEEE
[1]H. Ö. Kalaycı, M. K. Çalgın, H. Erdal, ve A. B. Gürpınar, “Distribution of hepatitis C virus genotypes in Ordu province”, TJCL, c. 16, sy 1, ss. 1–6, Mar. 2025, doi: 10.18663/tjcl.1554814.
ISNAD
Kalaycı, Hacer Özlem - Çalgın, Mustafa Kerem - Erdal, Hüseyin - Gürpınar, Ahmet Burak. “Distribution of hepatitis C virus genotypes in Ordu province”. Turkish Journal of Clinics and Laboratory 16/1 (01 Mart 2025): 1-6. https://doi.org/10.18663/tjcl.1554814.
JAMA
1.Kalaycı HÖ, Çalgın MK, Erdal H, Gürpınar AB. Distribution of hepatitis C virus genotypes in Ordu province. TJCL. 2025;16:1–6.
MLA
Kalaycı, Hacer Özlem, vd. “Distribution of hepatitis C virus genotypes in Ordu province”. Turkish Journal of Clinics and Laboratory, c. 16, sy 1, Mart 2025, ss. 1-6, doi:10.18663/tjcl.1554814.
Vancouver
1.Hacer Özlem Kalaycı, Mustafa Kerem Çalgın, Hüseyin Erdal, Ahmet Burak Gürpınar. Distribution of hepatitis C virus genotypes in Ordu province. TJCL. 01 Mart 2025;16(1):1-6. doi:10.18663/tjcl.1554814


e-ISSN: 2149-8296

The content of this site is intended for health care professionals. All the published articles are distributed under the terms of

Creative Commons Attribution Licence,

which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.